



# SEMPERIT GROUP Q1 2021 INVESTOR PRESENTATION

Dr Martin Füllenbach, CEO

Petra Preining, CFO

19 May 2021



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance (p.12)


Outlook (p.19)

Appendix (p.22)




# Highlights Q1 2021 – year-on-year comparison

## Revenue




## EBITDA




➤ Top-line up by >60% vs Q1'20 and >50% vs Q1'19  
- mainly driven by exceptional demand and high price levels at Medical Sector

➤ Operating profit at record level as higher revenues convert into strong EBITDA  
- due both to extraordinary performance of Medical Sector but also recovery at Industrial Sector

## NET PROFIT AFTER TAX



## FREE CASH-FLOW



➤ Both bottom line and FCF reflect not only high operating profit but also restructuring effort including significant cost savings

Figures in € million

<sup>1)</sup> Q1 2021 free cash flow of € 38.8m adjusted for investments in money market funds shares (€ -20m) included in investment cash flow



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance (p.12)

Outlook (p.19)


Appendix (p.22)




## Best quarter of the millennium

- Outstanding performance of Medical Sector continues both at top line and operating profit
- Industrial Sector: revenues up with mixed margins
- Operating Group EBITDA yoY improvement for 13th consecutive quarter

Revenue



EBITDA




- **Record top-line growth**
  - Medical Sector at € 192.9m, up by +149%
  - Industrial Sector at € 130.1m, up by +7%
- **EBITDA at € 122.2m with strong operating margin:**
  - Medical Sector continues to benefit from high price environment (€ 105.3m)
  - Industrial Sector: clear signs of rebound after corona-induced setback (EBITDA at € 20.6m exceeding Q1'20 )
- **EBIT at € 110.8m**



# Industrial Sector: top-line growth and margin recovery


With its trough in 2020, Industrial Sector in economic rebound despite margin pressure

### Revenues Q1'19-Q1'21



■ Revenue in € m

### Quarterly development EBITDA 2019-2021




■ EBITDA '19 in € m    — EBITDA '19 margin in %  
■ EBITDA '20 in € m    — EBITDA '20 margin in %  
■ EBITDA '21 in € m    ● EBITDA '21 margin in %




# Semperflex Q1 2021

EBITDA and margin close to strong Q1'19 level

Semperflex



## Q1 2021 vs. Q1 2020



- Revenue up due to better order intake on the back of positive market sentiment and significantly higher demand
- Order book after trend change at the end of 2020 clearly above last year's level
- Underlying profitability in visible recovery mode







# Sempertrans Q1 2021

External pressure due to corona crisis still impacting business

## Sempertrans



### Q1 2021 vs. Q1 2020



- Sluggish demand impact top line
- EBITDA still not at previous level but uptick compared to Q4'20
- EBITDA reduction mainly driven by volume difference
- Improvements in the project pipeline but first effects on business not to be expected before H2'2021



1) Q1'19 EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China








# Sempersal Q1 2021

Focus on specialty products and M&R consolidation boost top line and margins

Sempersal



## Q1 2021 vs. Q1 2020



- Industrial markets show a significant improvement vs. 2020
- Market share increased while order book consistently improved, being above Q1'20 level
- Successful integration of M&R ongoing with contribution to overall improved performance








# Semperform Q1 2021

First signs of top-line recovery but margins remain under pressure


Semperform



## Q1 2021 vs. Q1 2020



- Order intake and order book are improving and exceed Q1'20 levels
- Revenues at handrail and SES (especially railway, piping and household industries) above Q1'20, offsetting low demand from ski tourism (for cable car rings and ski foils)
- Margin pressure due to reductions in high margin businesses (ski tourism) and increasing raw materials' and logistics' price levels






# Medical Sector / Sempermed segment Q1 2021


Unprecedented growth in revenues and operating profit

Medical Sector

Sempermed



## Q1 2021 vs. Q1 2020



- Strong top line growth supported by very high production output running at full capacity
- Global supply-chain disruptions and container availability led to inventory built-up and lower operating cash flow in Q1'21
- Increased ASP and smoothly operating business on the back of timely safety and efficiency measures implied further improvement of EBITDA margins
- Strong order book: examination and surgical glove capacity for 2021 completely booked out while booking for 2022 almost completed



1) Q3'19 EBITDA adjusted for € 4m due to release of provision in Sempermed for Brazilian court case for tax liabilities



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)


Financial Performance (p.12)

Outlook (p.19)

Appendix (p.22)



# Revenue development




% change of each segment / sector refers to Q1 2021 vs. Q1 2020.



# Top line growth translates into higher reported EBITDA

Medical Sector strong - Industrial Sector increasingly resilient

in € m




	Q1 2020	Semperflex	Sempertrans	Semperseal	Semperform	Sempermed	Corporate	Q1 2021
EBITDA Q1 2020	16.9m	9.3m	1.6m	3.3m	3.5m	4.8m	-5.6m	
EBITDA Q1 2021		12.3m	1.0m	4.2m	3.1m	105.3m	-3.7m	122.2m
EBITDA margin Q1 2021	8.0%	22.5%	3.8%	14.7%	15.4%	54.6%	-	37.8%

Change of intercompany consolidation included in Corporate




# Overview of key financial KPIs, Q1'19-Q1'21

### EBITDA




— EBITDA margin, in %  
■ EBITDA, in € m

### EBIT



— EBIT margin, in %  
■ EBIT, in € m

### Earnings after tax




■ Earnings after tax, in € m



# Working Capital overview

## Components of Working Capital

in € m



<sup>1)</sup> Trade Working Capital in % of LTM revenues






# Free cash flow development and CAPEX

## Cash Flow Development

- Further improved results but headwinds from raw materials and shipping costs
- Operating CF driven by operating performance but also impacted by working capital development

## CAPEX

- Q1 2021 CAPEX at € 10.2 m – main focus on maintenance
- Outlook 2021: planned to be twice as high as low benchmark in 2020



<sup>1)</sup> Q1 2021 free cash flow adjusted for investments in money market funds shares (€ -20m) included in investment cash flow (in total € -31m)




# Balance sheet structure and financial profile

## Balance sheet structure

## Financial profile as of 30 March 2021

Balance sheet 30/03/2021: € 865m  
 Balance sheet 31/12/2020: € 764m



- **Cash and cash equivalents** of € 154m
- **Corporate Schuldschein loan** currently at € 170m – due in 2021 € ~80m
- **Net debt down** at € 15.3m, Net debt / EBITDA close to zero (YE'20: 0.1x)
- **Equity ratio** of 45.8% (YE'20:43.5%)
- **Hybrid fully repaid:** € 30m by the end of March '21



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance (p.12)

Outlook (p.19)

Appendix (p.22)



## Outlook 2021 and strategic focus areas

- Outlook confirmed: EBITDA guidance of € 395m maintained for 2021  
Focus on achieving this target against supply-chain constraints  
(especially with regards to the availability and pricing of raw materials and logistics)
- Strategy re-definition further advanced
- Strong cash position – sufficient to cover cash requirements in 2021 and providing strategic flexibility for future growth
- Developing comprehensive future ESG strategy



## Contact and financial calendar

### Investor Relations Semperit

**Judit Helenyi**, Director Investor Relations

+43 1 79777 - 310

[www.semperitgroup.com/en/ir](http://www.semperitgroup.com/en/ir)

Modecenterstrasse 22

1031 Vienna, Austria

### Financial Calendar 2021

19.05.2021

Report on Q1 2021

19.08.2021

Half-year financial report 2021

17.11.2021

Report on Q1-3 2021

#### Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



# Agenda

Key Highlights (p.2)

Operational Performance (p.4)

Financial Performance (p.12)

Outlook (p.19)

Appendix (p.22)



## Sectors and Group: Q1 2021 vs Q1 2020

in EUR m	Industrial Sector			Medical Sector			Semperit Group		
	Q1 2021	Q1 2020	%	Q1 2021	Q1 2020	%	Q1 2021	Q1 2020	%
<b>Revenue</b>	<b>130.1</b>	121.6	+7.0%	<b>192.9</b>	77.5	>100%	<b>323.1</b>	199.1	+62.3%
<b>EBITDA</b>	<b>20.6</b>	17.7	+16.8%	<b>105.3</b>	4.8	>100%	<b>122.2</b>	16.9	>100%
EBITDA margin	<b>15.9%</b>	14.5%	+1.3 PP	<b>54.6%</b>	6.1%	+48.4 PP	<b>37.8%</b>	8.5%	+29.4 PP
<b>EBIT</b>	<b>14.5</b>	11.4	+28.1%	<b>100.2</b>	4.3	>100%	<b>110.8</b>	9.8	>100%
EBIT margin	<b>11.2%</b>	9.3%	+1.8 PP	<b>52.0%</b>	5.5%	+46.5 PP	<b>34.3%</b>	4.9%	+29.4 PP
<b>Earnings after tax</b>	<b>-</b>	-	-	<b>-</b>	-	-	<b>85.5</b>	-1.7	>100%
<b>Earnings per share in EUR</b>	<b>-</b>	-	-	<b>-</b>	-	-	<b>4.13</b>	-0.17	>100%
<b>Additions in tangible and intangible assets</b>	<b>6.8</b>	3.8	+77.9%	<b>5.1</b>	0.9	>100%	<b>12.2</b>	4.8	>100%
<b>Employees</b>	<b>3,557</b>	3,600	-1.2%	<b>3,307</b>	3,301	+0.2%	<b>7,001</b>	7,046	-0.6%


Figures of Semperit Group also contain intercompany consolidation and the results of the Corporate Segment




# Semperit Group adj. where applicable

Semperit Group adj. where applicable																	
in EUR m	FY 2017 adj. <sup>1)</sup>	Q1 2018	Q2 2018 adj. <sup>2)</sup>	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. <sup>3)</sup>	Q4 2019 adj. <sup>4)</sup>	FY 2019	Q1 2020	Q2 2020 adj. <sup>5)</sup>	Q3 2020 adj. <sup>6)</sup>	Q4 2020 adj.	FY 2020 adj. <sup>7)</sup>	Q1 2021
<b>Revenue</b>	<b>874.2</b>	220.9	227.6	221.7	208.2	<b>878.5</b>	212.9	224.4	214.9	188.3	<b>840.6</b>	199.1	219.8	238.2	270.5	927.6	323.1
<b>EBITDA</b>	<b>35.8</b>	15.8	17.0	13.1	4.5	<b>50.3</b>	16.5	22.7	17.3	7.4	<b>63.8</b>	16.9	40.7	60.9	90.0	208.6	122.2
EBITDA margin	<b>4.1%</b>	7.1%	7.5%	5.9%	2.2%	<b>5.7%</b>	7.7%	10.1%	8.0%	3.9%	<b>7.6%</b>	8.5%	18.5%	25.6%	33.3%	22.5%	37.8%
<b>EBIT</b>	<b>-0.8</b>	6.0	7.2	4.3	-2.2	<b>15.4</b>	7.8	13.1	8.1	-0.7	<b>28.2</b>	9.8	33.6	49.2	78.8	171.4	110.8
EBIT margin	<b>-0.1%</b>	2.7%	3.2%	1.9%	-1.0%	<b>1.7%</b>	3.7%	5.8%	3.8%	-0.4%	<b>3.4%</b>	4.9%	15.3%	20.7%	29.1%	18.5%	34.3%

EBITDA adj. per quarter



EBIT adj. per quarter



<sup>1)</sup> Q1 2017 adj. for positive one-off effects from JV transaction of € 85m. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m EBITDA), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). <sup>2)</sup> Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA). <sup>3)</sup> Q3 2019 adjusted for negative one-off effect of € 47m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities. <sup>4)</sup> Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations <sup>5)</sup> Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect –20.0 Million EUR) <sup>6)</sup> Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). <sup>7)</sup> 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR –19.8 million)





# Semperflex and Sempertrans (adj. where applicable)

## Semperflex (Hoses)

	FY 2017 adj. <sup>1)</sup>	Q1 2018	Q2 2018	Q3 2018 adj. <sup>2)</sup>	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021
in EUR m																	
Revenue	206.1	58.8	62.8	53.4	55.1	230.0	61.1	59.7	53.8	48.0	222.7	46.8	51.5	46.6	45.0	189.9	54.7
EBITDA	41.4	13.7	14.9	9.3	10.9	48.9	13.9	14.5	10.8	8.7	47.9	9.3	14.0	11.4	7.2	41.9	12.3
EBITDA margin	20.1%	23.4%	23.8%	17.4%	19.8%	21.3%	22.8%	24.3%	20.1%	18.1%	21.5%	19.9%	27.2%	24.5%	16.0%	22.1%	22.5%
EBIT	32.7	11.1	12.3	6.9	8.1	38.4	11.1	11.5	7.7	5.7	36.0	6.5	11.2	8.7	4.5	30.9	9.6
EBIT margin	15.9%	18.9%	19.7%	12.9%	14.8%	16.7%	18.2%	19.2%	14.3%	11.9%	16.2%	13.9%	21.8%	18.6%	10.0%	16.3%	17.5%

## Sempertrans (Conveyor belts)

	FY 2017 adj. <sup>1)</sup>	Q1 2018	Q2 2018 adj. <sup>2)</sup>	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. <sup>3)</sup>	Q3 2020 adj. <sup>4)</sup>	Q4 2020 <sup>5)</sup>	FY 2020 adj. <sup>6)</sup>	Q1 2021
in EUR m																	
Revenue	146.0	34.6	37.0	37.6	35.5	144.8	30.4	37.8	35.1	30.6	134.0	29.5	32.5	28.4	22.7	113.1	26.9
EBITDA	-5.3	0.5	0.8	2.4	0.7	4.4	2.7	5.4	4.6	0.8	13.5	1.6	5.0	2.1	0.0	8.7	1.0
EBITDA margin	-3.6%	1.4%	2.1%	6.4%	2.1%	3.0%	9.0%	14.2%	13.1%	2.5%	10.1%	5.4%	15.4%	7.6%	0.0%	7.7%	3.8%
EBIT	-8.9	-0.4	-0.1	1.6	-0.4	0.7	1.8	3.8	3.6	-0.3	8.9	0.6	3.9	1.4	-0.6	4.9	0.2
EBIT margin	-6.1%	-1.1%	-0.2%	4.3%	-1.1%	0.5%	6.0%	10.0%	10.4%	-0.9%	6.7%	1.9%	11.9%	5.0%	-2.6%	4.3%	0.7%

<sup>1)</sup> Q1 2017 adj. for positive one-off effects from JV transaction of EUR 85 million. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (EUR 11 million) and valuation adjustment in IT (EUR 4 million EBITDA), expenses resulting from tax audit in Austria (EUR 5 million, mainly for refund of energy supply charge).

<sup>2)</sup> Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4 million for EBITDA).

<sup>3)</sup> Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempermed segment (EBIT effect: EUR 20.0 million).

<sup>4)</sup> Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

<sup>5)</sup> Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

<sup>6)</sup> 2020 Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)



# Semperform and Semperseal (adj. where applicable)

## Semperform (Window and door profiles, Handrails) - before 2020

in EUR m	FY 2017 adj.	Q1 2018	Q2 2018	Q3 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
Revenue	185.0	47.5	50.7	50.3	192.2	49.9	50.5	47.8	42.4	190.6
EBITDA	21.5	4.5	7.3	6.2	21.9	7.9	8.3	6.6	3.3	26.0
EBITDA margin	11.6%	9.6%	14.4%	12.2%	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%
EBIT	13.3	2.4	5.1	4.2	13.2	5.4	5.9	4.2	0.5	16.0
EBIT margin	7.2%	5.0%	10.1%	8.4%	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%

## Semperform (Window and door profiles, Handrails) - after 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021
Revenue	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4	19.6	81.8	19.8
EBITDA	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0	2.5	15.0	3.1
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%	12.9%	18.3%	15.4%
EBIT	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1	1.6	11.3	2.1
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%	8.0%	13.8%	10.8%

## Sempersal (Profiles and Rubber Sheeting) starting in 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021
Revenue	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4	22.2	93.6	28.7
EBITDA	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9	1.7	11.0	4.2
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%	7.5%	11.8%	14.7%
EBIT	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4	0.2	5.1	2.6
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%	1.1%	5.5%	9.2%

Split of former Semperform into Sempersal and Semperform as of 1<sup>st</sup> January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly



# Sempermed (adj. where applicable)

Sempermed (Gloves)																	
	FY 2017 adj. <sup>1) 2)</sup>	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. <sup>3)</sup>	Q4 2019	FY 2019 <sup>4)</sup>	Q1 2020	Q2 2020 adj. <sup>5)</sup>	Q3 2020 adj. <sup>6)</sup>	Q4 2020 <sup>7)</sup>	FY 2020 adj. <sup>8)</sup>	Q1 2021
in EUR m																	
<b>Revenue</b>	<b>337.1</b>	80.0	77.1	80.4	73.9	<b>311.5</b>	71.5	76.4	78.2	67.3	<b>293.3</b>	77.5	92.2	118.4	161.1	<b>449.2</b>	192.9
<b>EBITDA</b>	<b>1.8</b>	1.4	-1.3	-0.9	-3.1	<b>-3.9</b>	-0.9	0.6	1.8	-0.1	<b>1.4</b>	4.8	18.2	44.4	83.0	<b>150.4</b>	105.3
EBITDA margin	<b>0.5%</b>	1.8%	-1.7%	-1.1%	-4.2%	<b>-1.3%</b>	-1.2%	0.8%	2.3%	-0.1%	<b>0.5%</b>	6.1%	19.7%	37.5%	51.5%	<b>33.5%</b>	54.6%
<b>EBIT</b>	<b>-12.1</b>	-2.2	-5.1	-3.9	-3.1	<b>-14.3</b>	-2.8	-1.4	-0.3	-0.9	<b>-5.5</b>	4.4	17.6	38.9	77.8	<b>138.7</b>	100.2
EBIT margin	<b>-3.6%</b>	-2.8%	-6.6%	-4.8%	-4.2%	<b>-4.6%</b>	-3.9%	-1.9%	-0.4%	-1.4%	<b>-1.9%</b>	5.5%	19.1%	32.8%	48.3%	<b>30.9%</b>	52.0%

<sup>1)</sup> Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (EUR 2 million for Semperform, EUR 2 million for Sempermed)

<sup>2)</sup> Q3 2017 Sempermed adj. for positive one-off effects from JV transaction of EUR 78 million for EBITDA.

<sup>3)</sup> Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

<sup>4)</sup> 2019 adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR)

<sup>5)</sup> Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

<sup>6)</sup> Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

<sup>7)</sup> Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

<sup>8)</sup> 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)



## Key figures 2010-2020

Key performance figures											
in EUR m	2010 <sup>1)</sup>	2011 <sup>1)</sup>	2012	2013	2014 <sup>4)</sup>	2015 <sup>4)</sup>	2016 adj. <sup>4)</sup>	2017 adj. <sup>4)</sup>	2018 adj. <sup>5)</sup>	2019 adj. <sup>6)</sup>	2020 adj. <sup>7)</sup>
Revenue	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6	927.6
<b>EBITDA</b>	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6
EBITDA margin	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%
<b>EBIT</b>	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4
EBIT margin	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.4%	18.5%
<b>Earnings after tax</b>	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2	121.9
<b>Gross cash flow</b>	91.0	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.70	193.7
<b>Return on equity</b>	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%

Balance sheet key figures											
in EUR m	2010 <sup>1)</sup>	2011 <sup>1)</sup>	2012	2013	2014 <sup>4)</sup>	2015 <sup>4)</sup>	2016	2017	2018	2019	2020
<b>Balance sheet total</b>	593.5	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4
<b>Equity</b>	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	273.4	332.3
<b>Equity ratio</b>	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%
<b>Investments in tangible and intangible assets (CAPEX)</b>	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4
<b>Employees, at balance sheet date, FTEs</b>	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943


<sup>1)</sup> 2011 restated (see Annual Report 2012, Notes 2.18), 2010 not restated. <sup>2)</sup> 2014 and 2015 restated. <sup>3)</sup> 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. <sup>4)</sup> 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). <sup>5)</sup> 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only). <sup>6)</sup> FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). <sup>7)</sup> 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million)



# CAPEX by quarter

## CAPEX per segment


in € m





# Overview price indices Butadiene

Price movements for raw materials<sup>1)</sup> became highly unpredictable




<sup>1)</sup> Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



# Overview price indices LFO-F-NWE / wire rod

## Significant increase for raw material<sup>1)</sup> used in industrial segments



<sup>1)</sup> Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



# Product / market position / segment overview, FY 2020

in EUR m

## Semperit Group

Group	Industrial Sector				Medical Sector	
	Semperflex	Sempertrans	Semperform <sup>4)</sup>	Semperseal <sup>4)</sup>	Sempermed	
Revenue	927.6	189.9 / 20% <sup>1)</sup>	113.1 / 12% <sup>1)</sup>	81.8 / 9% <sup>1)</sup>	93.6 / 10% <sup>1)</sup>	449.2 / 48% <sup>1)</sup>
EBITDA	208.6 <sup>2)</sup>	41.9	8.7	15.0	11.0	150.4
Employees	6,943 <sup>2)</sup>	1,571 / 23% <sup>3)</sup>	917 / 13% <sup>3)</sup>	520 / 7% <sup>3)</sup>	457 / 7% <sup>3)</sup>	3,337 / 48% <sup>3)</sup>

### Products and market position

#### Hydraulic hoses

# 3 position globally / leader in hose only



#### Industrial hoses

# 2 - 3 position in Europe



#### Conveyor belts

One of the leading providers for heavy-duty steel and textile cord belts



#### HSA\* / SES\*\*

Leading European manufacturers of moulded and extrusion products made of rubber and plastics (handrails, cable car rings, ski foils and Engineered Solutions)



#### Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting (construction, packaging, machinery, HVAC, marine, electric systems)



#### Examination gloves

Among the top 15 glovemakers in the world



#### Surgical gloves

Among the leading companies in Europe



\*Handrails, Special Applications  
\*\* Semperit Engineered Solutions

<sup>1)</sup> Revenue in % of Group revenue.

<sup>2)</sup> Group figure includes corporate center of € -18m, 136 employees.

<sup>3)</sup> Employees in % of Group employees.

<sup>4)</sup> The business units Profiles and Rubber


Sheeting were separated from the Semperform segment and are operated as individual segments under the name Semperseal as of 1 January 2020.





## Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C